Valeriy Meladze to Perform in Israel's Caesarea Amphitheater
Translated & summarized from Mignews by baba
Russian singer Valeriy Meladze will hold a special concert on October 28, 2026, at the ancient Caesarea Amphitheater in Israel. This performance, part of his world tour, follows his successful 2025 Israeli shows and will feature his greatest hits and new material. The concert is organized by YM Productions and AY Productions and is expected to be a romantic evening for his fans.
The story in 5 lines · by baba
- Valeriy Meladze will perform a concert in Israel on October 28, 2026.
- The concert will take place at the historic Caesarea Amphitheater.
- This event follows successful sold-out performances by Meladze in 2025.
- The program will include his most popular hits and new songs.
- YM Productions and AY Productions are the organizers of the event.
Russian pop singer Valeriy Meladze is scheduled to perform a single concert in Israel on October 28, 2026, at the Caesarea Amphitheater. This marks his return to Israel following successful sold-out shows in 2025, responding to public demand. The concert will feature a new program presented in one of Israel's most romantic open-air venues, set against ancient ruins and the Mediterranean Sea.
Meladze, known for his romantic music over a 30-year career and collaborations with his brother Konstantin Meladze, will present a jubilee program. This world tour program includes both his most popular hits and new songs. The concert is expected to feature well-known songs such as "How Beautiful You Are Today," "Sera," and "I Can't Without You."
Organizers YM Productions and AY Productions, led by Mark Yurik and Alon Yurik, are promoting the event. Tickets are available through Eventim. The event promises an evening of romance, nostalgia, and emotion, with the singer aiming for a direct dialogue with his audience. The concert is scheduled to begin at 8:30 PM.
Mentioned
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
